

Peter W Butler

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4662539/peter-w-butler-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8

papers

235

citations

7

h-index

8

g-index

8

ext. papers

314

ext. citations

5.9

avg, IF

2.53

L-index

#	Paper	IF	Citations
8	Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. <i>European Journal of Endocrinology</i> , 2010 , 163, 863-72	6.5	61
7	Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1174-1184	9.5	59
6	The Thr92Ala 5atype 2 deiodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study. <i>Thyroid</i> , 2010 , 20, 1407-12	6.2	46
5	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2443-2452	5.6	23
4	The -258A/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRH-induced acute rise in TSH. <i>European Journal of Endocrinology</i> , 2012 , 166, 839-45	6.5	16
3	Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: clinical experience following tumor resection and long-acting octreotide therapy. <i>Pituitary</i> , 2012 , 15, 260-5	4.3	13
2	Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3450-3461	5.6	11
1	Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. <i>Bone</i> , 2020 , 134, 115287	4.7	6